The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended three medications for approval during its April meeting.

The treatments proposed include Gilead’s HIV-1 treatment Biktarvy, AcelRx Pharmaceuticals’ hybrid pain therapy Dzuveo (sufentanil), and Obvius Investment’s  Carmustine Obvius (carmustine), a generic treatment for brain tumours, non-Hodgkin’s lymphoma and Hodgkin’s disease.

CHMP is to consider a marketing authorisation for all three treatments.

Biktarvy is a once-daily single tablet regimen containing three active substances: bictegravir, emtricitabine and tenofovir alafenamide.

The drug has previously demonstrated efficacy in virologic suppression and no treatment-emergent resistance in Phase III trials. The marketing application contains data from four Phase III studies where the drug reached its primary goal of non-inferiority to ViiV Healthcare’s flagship drug dolutegravir (DTG) at 48 weeks. The drug was approved in the US in February.

The hybrid medication Dzuveo received a positive opinion for pain treatment, though the success of its application will be reliant on the results of preclinical tests and clinical trials due to its hybrid status. The drug, which has been authorised in the EU since 1978, is an opioid which produces analgesia through activating μ-opioid receptors within the central nervous system. Its most common adverse effects include nausea, vomiting and pyrexia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Carmustine Obvius is a generic of the cancer medication Carmubris, which has been authorised in the EU since July 1996. The drug prevents DNA replication and transcription by alkylating reactive sites on nucleoproteins. As the generic is administered intravenously and is 100% bioavailable, CHMP does not require a bioequivalence study against the original Carmubris.

The EMA also announced its decision to re-examine the applications for Dexxience (betrixaban), Alsitek (masitinib) and Eladynos (abaloparatide), which received negative responses during the March 2018 meeting. These are treatments intended for venous thromboembolism, amyotrophic lateral sclerosis (ALS) and osteoporosis, respectively.

An initial marketing authorisation for Prohippur (sodium benzoate) was withdrawn following the April meeting. This was intended to be a treatment for non-ketotic hyperglycinaemia and urea cycle disorders. Similarly, an application for the extension of the use of Qtern (saxagliptin/dapagliflozin) in patients with type 2 diabetes was withdrawn.